Covalent Drug Binding
Covalent Drug Binding - Related Videos
02:18
Network Covalent Solids
0 Views •
2020
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds. To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
02:04
Covalently Linked Protein Regulators
0 Views •
2020
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified. These groups modify specific amino acids in a protein.
10:23
Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
0 Views •
Cited by 8 •
2013
We describe a method for accomplishing efficient immobilization of BMP-2 on surfaces. Our approach is based on the formation of a self-assembled monolayer to achieve the covalent binding of BMP-2 via its free amine residues. This method is a useful tool to study signaling at the cell membrane.
01:18
Factors Affecting Protein-Drug Binding: Drug-Related Factors
0 Views •
2025
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body. One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
02:46
Covalent Bonding and Lewis Structures
0 Views •
2020
Compared to ionic bonds, which results from the transfer of electrons between metallic and nonmetallic atoms, covalent bonds result from the mutual attraction of atoms for a “shared” pair of electrons. Covalent bonds are formed between two atoms when both have similar tendencies to attract electrons to themselves (i.e., when both atoms have identical or fairly similar ionization energies and electron affinities). Physical Properties of Covalent Compounds Compounds that contain covalent...
FAQs
Target recognition and bond formation occur as linked but distinct events. The small molecule first fits a complementary binding site, positioning its electrophilic warhead near a nucleophilic residue on the biological target. That arrangement enables the chemical reaction rather than relying on nonspecific reactivity, helping explain why site recognition is central to useful covalent pharmacology.
The warhead supplies the electrophilic reaction partner, whereas the protein contributes the nucleophilic site. The overview identifies cysteine, serine, and lysine as possible residues, so the target protein's available chemistry influences which compounds can engage it. This division of roles connects molecular recognition with formation of a specific chemical bond.
A durable chemical bond can strengthen target engagement, but an electrophilic group may also react with unintended proteins. Drug design therefore must balance sufficient reactivity for the intended target against selectivity for other biological components. Achieving that balance can preserve potency and duration while limiting unwanted binding and potential safety concerns.
Covalent engagement can last longer than noncovalent interaction because the drug forms a chemical bond with its target. Reversible covalent compounds are being developed to retain controlled chemical engagement while allowing greater control over binding and safety. These approaches represent different ways to combine molecular recognition, duration, and manageability in pharmacological design.
Design begins by identifying a complementary binding site and a suitable nucleophilic residue on the biological target. An electrophilic warhead can then be incorporated so recognition positions it for reaction. The resulting compound must be evaluated for durable engagement, potency, and selectivity, because excessive reactivity could increase unintended protein binding.
Covalent inhibitors are investigated when durable target engagement could support treatment of disease. The provided context identifies cancer, infectious diseases, and inflammatory disorders as major medical areas. In each setting, researchers must connect the desired biological effect with an acceptable selectivity profile, since the same chemical reactivity that supports inhibition may also create unintended interactions.
Reversible covalent compounds address a key design goal: combining chemical target engagement with greater control over binding and safety. They are being developed as an alternative to relying only on fully durable interactions. This research direction is especially relevant when prolonged engagement may improve pharmacology but uncontrolled or unintended protein reactions could limit clinical usefulness.